Skip to content
Head to head

Aurinia Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: AUPH · VRTX

Updated moments ago

1-year performance, rebased to 100

AUPH -5.1%VRTX +18.7%
It’s close.
AUPHVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price14.70515.02
Change today-1.28%-1.08%
1-year return-2.9%+22.0%
Market cap$1.97B$130.58B
52-week range13.52 – 19.25412.27 – 568.67
Valuation
P/E (TTM)6.4533.14
P/E percentile, own 5-yr range67th99th
P/B3.006.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.0715.32
Net profit (TTM)$277.38M$3.88B
Revenue (TTM)$321.74M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+13.9%+11.8%
Gross margin90.6%85.5%
Operating margin48.6%33.1%
Net margin97.7%30.7%
Free cash flow (TTM)$177.03M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership67.1%96.8%
Insider activity (12mo)27 buy / 23 sell28 buy / 22 sell
Short interest (% of float)5.3%1.9%
Analyst consensus67% buy / 33% hold (3)95% buy / 5% hold (21)
Analyst price target$19 (+29%)$624 (+21%)
StockVane view
StockVane Quant RatingD (36)C (68)
Company
Employees1286,400
Founded19931989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.